The stock of MacroGenics Inc (NASDAQ:MGNX) is a huge mover today! About 107,482 shares traded hands. MacroGenics Inc (NASDAQ:MGNX) has risen 0.40% since April 4, 2016 and is uptrending. It has underperformed by 0.69% the S&P500.
The move comes after 6 months positive chart setup for the $726.63M company. It was reported on Nov, 4 by Barchart.com. We have $26.36 PT which if reached, will make NASDAQ:MGNX worth $188.92M more.
MacroGenics Inc (NASDAQ:MGNX) Ratings Coverage
Out of 4 analysts covering MacroGenics (NASDAQ:MGNX), 2 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 50% are positive. MacroGenics has been the topic of 8 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The stock of MacroGenics Inc (NASDAQ:MGNX) has “Neutral” rating given on Thursday, September 17 by Citigroup. The firm earned “Buy” rating on Monday, October 19 by Citigroup. The stock of MacroGenics Inc (NASDAQ:MGNX) has “Buy” rating given on Thursday, August 6 by Stifel Nicolaus. The firm earned “Equal-Weight” rating on Thursday, February 25 by Morgan Stanley. The rating was initiated by Janney Capital with “Buy” on Thursday, February 18. As per Monday, August 10, the company rating was downgraded by Zacks. Citigroup downgraded it to “Neutral” rating and $32 target price in Thursday, August 4 report.
According to Zacks Investment Research, “MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland.”
Insitutional Activity: The institutional sentiment decreased to 1.21 in Q2 2016. Its down 0.17, from 1.38 in 2016Q1. The ratio turned negative, as 14 funds sold all MacroGenics Inc shares owned while 34 reduced positions. 13 funds bought stakes while 45 increased positions. They now own 27.76 million shares or 2.47% less from 28.46 million shares in 2016Q1.
Vident Invest Advisory Ltd Liability Com last reported 0.1% of its portfolio in the stock. Ubs Asset Americas owns 556,344 shares or 0.02% of their US portfolio. California State Teachers Retirement System accumulated 66,849 shares or 0% of the stock. Cormorant Asset Mgmt Ltd Liability Corporation last reported 2.71% of its portfolio in the stock. Emerald Advisers Incorporated Pa holds 0.47% of its portfolio in MacroGenics Inc (NASDAQ:MGNX) for 361,143 shares. Strs Ohio owns 7,700 shares or 0% of their US portfolio. Muhlenkamp Company Inc holds 15,835 shares or 0.17% of its portfolio. Ladenburg Thalmann Svcs last reported 2,081 shares in the company. Oxford Asset Mgmt has 0.11% invested in the company for 96,417 shares. Orbimed Advisors Lc has 0.04% invested in the company for 149,400 shares. Dafna Cap Mngmt Ltd Com holds 54,200 shares or 1.16% of its portfolio. Paradigm Asset Mgmt Ltd Llc last reported 0% of its portfolio in the stock. Tanaka Cap, a New York-based fund reported 26,170 shares. Point72 Asset Mgmt Limited Partnership owns 2.55M shares or 0.47% of their US portfolio. Citadel Advsrs Lc reported 27,534 shares or 0% of all its holdings.
Insider Transactions: Since May 27, 2016, the stock had 0 insider buys, and 6 insider sales for $1.60 million net activity. $242,857 worth of shares were sold by Cilinski Lynn on Friday, July 1. The insider Wigginton Jon Marc sold $615,600.
More recent MacroGenics Inc (NASDAQ:MGNX) news were published by: Marketwatch.com which released: “Plus the latest data from Realtor.com on 21 home markets across the US” on November 04, 2013. Also Streetinsider.com published the news titled: “Form S-8 MACROGENICS INC” on November 02, 2016. Globenewswire.com‘s news article titled: “MacroGenics Enters Collaboration and License Agreement with Janssen to Develop …” with publication date: May 18, 2016 was also an interesting one.
MGNX Company Profile
MacroGenics, Inc., incorporated on August 14, 2000, is a clinical-stage biopharmaceutical firm focused on discovering and developing monoclonal antibody therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Firm operates through developing monoclonal antibody therapeutics for cancer, autoimmune and infectious diseases segment. The Firm develops therapeutic product candidates using its antibody technology platforms and in partnership with other biopharmaceutical companies. The Firm has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created primarily using its technology platforms.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.